C07K 2317/70
Characterized by effect upon binding to a cell or to an antigen
Official title: characterized by effect upon binding to a cell or to an antigen
C07K2317/70 (Characterized by effect upon binding to a cell or to an antigen) appears on 18,580 US grants and 36,360 published applications in this corpus.
Search patents in C07K- Granted patents
- 18,580
- Published applications
- 36,360
- Assignees
- 6,633
- Inventors
- 43,188
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 2 | 0 |
| 1986 | 2 | 0 |
| 1987 | 3 | 0 |
| 1988 | 4 | 0 |
| 1989 | 4 | 0 |
| 1990 | 10 | 0 |
| 1991 | 4 | 0 |
| 1992 | 7 | 0 |
| 1993 | 17 | 0 |
| 1994 | 10 | 0 |
| 1995 | 19 | 0 |
| 1996 | 38 | 0 |
| 1997 | 70 | 0 |
| 1998 | 90 | 0 |
| 1999 | 90 | 0 |
| 2000 | 93 | 0 |
| 2001 | 85 | 29 |
| 2002 | 99 | 193 |
| 2003 | 81 | 285 |
| 2004 | 88 | 303 |
| 2005 | 74 | 456 |
| 2006 | 129 | 513 |
| 2007 | 148 | 587 |
| 2008 | 230 | 610 |
| 2009 | 303 | 906 |
| 2010 | 423 | 969 |
| 2011 | 495 | 1121 |
| 2012 | 567 | 1087 |
| 2013 | 709 | 1226 |
| 2014 | 777 | 1433 |
| 2015 | 886 | 1608 |
| 2016 | 991 | 1947 |
| 2017 | 1105 | 1952 |
| 2018 | 1096 | 1951 |
| 2019 | 1223 | 2176 |
| 2020 | 1336 | 2280 |
| 2021 | 1317 | 2540 |
| 2022 | 1266 | 2629 |
| 2023 | 1159 | 2488 |
| 2024 | 1304 | 2896 |
| 2025 | 1347 | 2473 |
| 2026 | 877 | 1702 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C07K 2317/76Antagonist effect on antigenIndexing code12,218
- C07K 2317/73Inducing cell deathIndexing code7,733
- C07K 2317/77Internalization into the cellIndexing code1,960
- C07K 2317/75Agonist effect on antigenIndexing code1,447
- C07K 2317/71Decreased effector function due to an fc-modificationIndexing code1,006
- C07K 2317/74Inducing cell proliferationIndexing code793
- C07K 2317/72Increased effector function due to an fc-modificationIndexing code615
Recent patents
- Compositions and methods of treating lupus nephritis6 Oct 2026US 12,752,005 B2Genentech, Inc.
- Antibodies binding to alpha-synuclein for therapy and diagnosis6 Oct 2026US 12,753,223 B2AC Immune SA
- Anti-MS4A4A antibodies and methods of use thereof6 Oct 2026US 12,753,225 B2Alector LLC
- TGFbeta1-binding immunoglobulins and use thereof6 Oct 2026US 12,753,226 B2Scholar Rock, Inc.
- Antibodies against human TSLP and use thereof6 Oct 2026US 12,753,227 B2Beijing Wisdomab Biotechnology Co., Ltd
- Methods of decreasing pathological neuroinflammation8 Oct 2026US 2026/0306585 A1Washington University
- Radiolabeled met binding proteins for immuno-pet imaging8 Oct 2026US 2026/0306682 A1Regeneron Pharmaceuticals, Inc.
- Thin Wall Cannula8 Oct 2026US 2026/0306753 A1Becton, Dickinson and Company
- Methods and compositions for treating cancer8 Oct 2026US 2026/0308241 A1Chugai Seiyaku Kabushiki Kaisha
- Methods of treating inflammatory diseases8 Oct 2026US 2026/0308246 A1Boehringer Ingelheim International GmbH
Most cited
By later US patents
- Humanized immunoglobulins2,884US 5,585,089 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,259US 5,530,101 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,030US 5,693,762 AProtein Design Labs, Inc. · 1997
- Humanized immunoglobulins and methods of making the same1,467US 6,180,370 B2Protein Design Labs, Inc. · 2001
- Immunoglobulin variants1,380US 5,821,337 AGenentech, Inc. · 1998